BHCM
KYTX icon

Brevan Howard Capital Management’s Kyverna Therapeutics KYTX Stock Holding History

Brevan Howard Capital Management’s Portfolio KYTX Stock Details KYTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q2 		– Sell
-11,435
Closed -$284K – 1446
2024
Q1 		$284K Buy
+11,435
New +$319K ﹤0.01% 679

Other funds holding KYTX

GGI
GordonMD Global Investments Beverely Hills, California $144M AUM
GS
Gilead Sciences Foster City, California $2.12B AUM 143.53% 1-Year Est. Return
BCLSI
Bain Capital Life Sciences Investors Boston, Massachusetts $1.11B AUM 171.34% 1-Year Est. Return
ACM
AIGH Capital Management Baltimore, Maryland $733M AUM 327.32% 1-Year Est. Return
DM
Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Balyasny Asset Management
Balyasny Asset Management Chicago, Illinois $77.1B AUM 42.89% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
IHG
Insight Holdings Group New York $1.42B AUM 41.03% 1-Year Est. Return

Brevan Howard Capital Management's KYTX Position: Q2 2024 in Review

Brevan Howard Capital Management sold out of Kyverna Therapeutics (KYTX) in Q2 2024, closing a stake of 11,435 shares — an estimated $284K sold.

Brevan Howard Capital Management first reported a position in KYTX in Q1 2024 and held it in 1 quarter. The position peaked at $284K in Q1 2024. 88 funds tracked by Wall St. Rank hold KYTX as of Q2 2024.

  • Brevan Howard Capital Management reported no remaining Kyverna Therapeutics position as of Q2 2024 after selling out during the quarter.
  • Brevan Howard Capital Management sold 11,435 Kyverna Therapeutics shares in Q2 2024, an estimated $284K.
  • Brevan Howard Capital Management first reported a position in Kyverna Therapeutics in Q1 2024 and held it in 1 quarter.
  • Brevan Howard Capital Management's Kyverna Therapeutics position peaked at $284K in Q1 2024.
  • 88 funds tracked by Wall St. Rank held Kyverna Therapeutics as of Q2 2024.

Based on Brevan Howard Capital Management's 13F filing for Q2 2024, filed 14 Aug 2024.